# Drugs detected in suspected pediatric exposures: a 5-year review. > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/pediatric-cannabis-exposure-emergency-department-detection-study/ > **Published:** 2026-04-29T05:02:10-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T09:59:31-04:00 > **Clinical Summary:** New study reveals cannabis metabolites among most detected compounds in pediatric emergency visits with suspected toxic exposures across two hospitals. --- CED Clinical Relevance  #56Monitored Relevance Evidence Brief | CED ClinicCannabis metabolites were among the most frequently detected substances in pediatric patients presenting with suspected toxic exposures in a 5-year multi-hospital study. PediatricCannabisToxicology[Emergency Medicine](https://cedclinic.com/cannabis-hyperemesis-syndrome-increasing-glen-cove/)[Drug Testing](https://cedclinic.com/how-long-does-weed-stay-in-your-system/) Cannabis metabolites were among the most frequently detected substances in pediatric patients presenting with suspected toxic exposures in a 5-year multi-hospital study. What This Study Teaches Us This surveillance study provides contemporary data on the landscape of pediatric toxic exposures, showing cannabis metabolites rank among the most commonly detected substances alongside caffeine, nicotine, and common medications. The finding that comprehensive testing detected substances in 85% of specimens while immunoassays were positive in only 33% demonstrates the limitations of standard screening approaches. Why This Matters For clinicians managing pediatric exposures, this data informs testing strategies and highlights that cannabis exposure is a frequent consideration in this population. The high detection rate of cannabis metabolites suggests either intentional use in older pediatric patients or unintentional exposure in younger children, both clinically relevant scenarios. Study Snapshot Study Type Retrospective Cohort Study Population Pediatric patients with suspected toxic ingestions at two hospitals, over 6,000 specimens analyzed Intervention Urine immunoassay screens and comprehensive gas chromatography-mass spectrometry toxicology analysis Comparator None – descriptive study Primary Outcome Frequency of drug detection by compound class Key Finding Cannabis metabolites (carboxy-THC) were among the most frequently detected compounds; cannabinoid immunoassays positive in 33% of specimens Journal Clinical Toxicology Year Not specified in abstract Clinical Bottom Line Cannabis metabolite detection is common in pediatric patients presenting with suspected toxic exposures, warranting consideration in [differential diagnosis](https://cedclinic.com/meningitis-mortality-global-study/) and testing protocols. Comprehensive toxicology testing reveals substantially more exposures than standard immunoassays alone. What This Paper Does Not Show The abstract does not specify patient ages, clinical outcomes, intentional versus unintentional exposures, or the clinical significance of detected substances. It cannot establish whether detected cannabis metabolites caused symptoms or were incidental findings from prior use. Where This Paper Deserves Skepticism Detection of metabolites does not establish causation for presenting symptoms, and cannabis metabolites can persist long after [acute effects](https://cedclinic.com/episodic-memory-cannabis-impairment-study/) resolve. The study design cannot distinguish between recent exposure causing symptoms versus detection of prior use unrelated to the clinical presentation. Dr. Caplan's Take This reinforces what we see clinically – cannabis exposure in pediatric populations is more common than many realize. However, positive tests require careful interpretation since THC metabolites persist well beyond acute intoxication. The key clinical question isn’t whether cannabis was detected, but whether it explains the child’s current presentation. What a Careful Reader Should Take Away Cannabis metabolites are frequently detected in pediatric toxic exposure cases, reflecting either intentional adolescent use or unintentional pediatric ingestion. Detection requires clinical correlation to determine relevance to the presenting syndrome, and comprehensive testing reveals more exposures than standard screening panels. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Drugs%20detected%20in%20suspected%20pediatric%20exposures%3A%20a%205-year%20review.%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2Fpediatric-cannabis-exposure-emergency-department-detection-study%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fpediatric-cannabis-exposure-emergency-department-detection-study%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Drugs%20detected%20in%20suspected%20pediatric%20exposures%3A%20a%205-year%20review.%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2Fpediatric-cannabis-exposure-emergency-department-detection-study%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Table of Contents - [FAQ](#FAQ)[How common are cannabis metabolites in pediatric patients presenting with suspected toxic exposures?](#How_common_are_cannabis_metabolites_in_pediatric_patients_presenting_with_suspected_toxic_exposures) - [What is the difference in detection rates between immunoassay screening and comprehensive toxicology testing?](#What_is_the_difference_in_detection_rates_between_immunoassay_screening_and_comprehensive_toxicology_testing) - [Should cannabis testing be routinely included in pediatric toxicology workups?](#Should_cannabis_testing_be_routinely_included_in_pediatric_toxicology_workups) - [What other substances are commonly detected alongside cannabis in pediatric toxic exposures?](#What_other_substances_are_commonly_detected_alongside_cannabis_in_pediatric_toxic_exposures) - [How should clinicians interpret positive cannabis results in pediatric patients with suspected ingestion?](#How_should_clinicians_interpret_positive_cannabis_results_in_pediatric_patients_with_suspected_ingestion) - [Related](#Related) ## FAQ #### How common are cannabis metabolites in pediatric patients presenting with suspected toxic exposures? Cannabis metabolites (carboxy-tetrahydrocannabinol) were among the most frequently detected compounds in this 5-year study of over 6,000 pediatric cases. Cannabinoid immunoassays were one of the most commonly positive drug screens, found in 33% of specimens testing positive for drugs of abuse. #### What is the difference in detection rates between immunoassay screening and comprehensive toxicology testing? Drug immunoassays detected substances in 33% of specimens, while comprehensive gas chromatography-mass spectrometry detected drugs in 85% of specimens. This significant difference highlights the superior sensitivity of comprehensive testing methods for identifying toxic exposures in pediatric patients. #### Should cannabis testing be routinely included in pediatric toxicology workups? Yes, given that cannabinoids were among the most frequently positive immunoassays in suspected pediatric exposures. Cannabis testing should be considered as part of standard toxicology screening protocols, especially given changing legal landscapes and increased accessibility of cannabis products. #### What other substances are commonly detected alongside cannabis in pediatric toxic exposures? The most frequently detected compounds included caffeine, nicotine, antihistamines, antipyretics, antidepressants, antipsychotics, and anticonvulsants. This pattern suggests that pediatric exposures often involve multiple household substances and medications rather than isolated cannabis exposure. #### How should clinicians interpret positive cannabis results in pediatric patients with suspected ingestion? Positive cannabis metabolite detection indicates exposure but requires clinical correlation with symptoms and exposure history. Given that carboxy-THC can persist for days to weeks, positive results may not necessarily indicate acute intoxication but rather recent exposure requiring appropriate [clinical assessment](https://cedclinic.com/cannabis-use-disorder-neurobiology-attention-findings/) and intervention. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).